Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) announced on October 1, 2025 that it granted inducement awards under its 2023 Inducement Plan to 10 new employees to purchase up to 138,900 shares of common stock. The awards are stock options that vest over four years: 25% vest on the one‑year anniversary of the vesting commencement date and the remaining shares vest monthly at 1/48th per month over the following 36 months, subject to continued service. The grants were reported under Nasdaq Listing Rule 5635(c)(4).

News Market Reaction

+5.13%

1 alert

+5.13% News Effect

On the day this news was published, SNDX gained 5.13%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

FAQ

What did Syndax (SNDX) announce on October 1, 2025 regarding inducement grants?

Syndax granted inducement stock options to 10 new employees to purchase up to 138,900 shares under the 2023 Inducement Plan.

How do the SNDX inducement options vest and when do they start vesting?

Options vest over four years: 25% on the one‑year anniversary, then monthly at 1/48th for 36 months thereafter, subject to continued service.

Under which Nasdaq rule did Syndax report the October 1, 2025 inducement awards?

The awards were reported under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards in the Syndax October 2025 grant?

The company granted inducement awards to 10 new employees.

Are the Syndax inducement awards part of an existing plan and which one?

Yes — the awards were granted under Syndax's 2023 Inducement Plan.

Do the inducement grants immediately dilute SNDX shares after October 1, 2025?

The grants are options to purchase up to 138,900 shares; dilution occurs only if and when options are exercised per their vesting schedule.